Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ditzel

Showing results (291-300 of 314) with videos related to

Pageof 32
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2022
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancerLi-Teng Ong, Wee Chyan Lee, Shijun Ma, et al.
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2015
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung CancerTom Donnem, Sigurd M Hald, Erna-Elise Paulsen, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2025
Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibitionMie K Jakobsen, Sofie Traynor, Aaraby Y Nielsen, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.
Cancer & Metabolism|June 6, 2019
Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of <i>SDHC</i>Gro V Røsland, Sissel E Dyrstad, Deusdedit Tusubira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Ebiomedicine|April 13, 2023
Macrophage CD5L is a target for cancer immunotherapyLidia Sanchez-Moral, Tony Paul, Clara Martori, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Pageof 32

Showing results (291-300 of 314) with videos related to

Sort By:
Pageof 32
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2022
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancerLi-Teng Ong, Wee Chyan Lee, Shijun Ma, et al.
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2015
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung CancerTom Donnem, Sigurd M Hald, Erna-Elise Paulsen, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2025
Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibitionMie K Jakobsen, Sofie Traynor, Aaraby Y Nielsen, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.
Cancer & Metabolism|June 6, 2019
Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of <i>SDHC</i>Gro V Røsland, Sissel E Dyrstad, Deusdedit Tusubira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Ebiomedicine|April 13, 2023
Macrophage CD5L is a target for cancer immunotherapyLidia Sanchez-Moral, Tony Paul, Clara Martori, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Pageof 32